Cyclooxygenase Inhibitors, Glucocorticoids, and Gout Pharmacotherapy

Cyclooxygenase (COX)

The key enzyme responsible for synthesizing prostaglandins and thromboxane from arachidonic acid, existing in two primary isoforms: COX-1 and COX-2.

Cyclooxygenase-1 (COX-1)

The constitutive cyclooxygenase isoform found in tissues such as the stomach, platelets, and kidneys, where it mediates baseline protective and physiological functions.

Cyclooxygenase-2 (COX-2)

The cyclooxygenase isoform found in blood vessels, injured tissues, the brain, kidneys, and colon, predominantly responsible for mediating inflammation, pain, fever, and vasodilation.

Prostaglandin E2 ($\text{PGE}_2$) in the Stomach

A COX-1 reaction product in gastric tissue that promotes gastric protection by increasing bicarbonate secretion, stimulating mucus production, and decreasing acid secretion.

Prostaglandin I2 ($\text{PGI}_2$ / Prostacyclin) in the Stomach

A gastric COX-1 product that contributes to mucosal defense by preserving submucosal blood flow and inhibiting acid secretion.

Thromboxane A2 ($\text{TXA}_2$)

A COX-1 reaction product synthesized within platelets that stimulates platelet aggregation and clot formation.

Prostacyclin in Blood Vessels

A COX-2 reaction product generated in vascular walls that produces vasodilation and counteracts excessive thrombosis.

Gastric Protection via COX-1

A physiological defense mechanism consisting of increased bicarbonate secretion, increased mucus production, decreased acid secretion, and maintenance of submucosal blood flow.

Gastric Ulceration from COX Inhibition

An adverse gastrointestinal outcome triggered when COX-1 inhibitors block protective prostaglandins ($\text{PGE}_2$ and $\text{PGI}_2$) in the stomach lining.

Table 70-1: Cyclooxygenase-1 and Cyclooxygenase-2: Functions and Effect of Inhibition

A reference table outlining the physiological distribution, reaction products ($\text{PGE}_2$, $\text{PGI}_2$, $\text{TXA}_2$, prostacyclin), biological responses, and clinical consequences of inhibiting COX-1 and COX-2.

Platelet Aggregation via COX-1

The physiological clumping of blood platelets driven by platelet COX-1 synthesis of thromboxane A2 ($\text{TXA}_2$).

Bleeding Tendencies from COX-1 Inhibition

An adverse effect caused by pharmacological inhibition of platelet COX-1, which suppresses thromboxane A2 ($\text{TXA}_2$) and impairs primary hemostasis.

Protection Against Myocardial Infarction (MI) via COX-1 Inhibition

The therapeutic antiplatelet benefit achieved through irreversible suppression of platelet aggregation by aspirin.

Vascular Vasodilation via COX-2

The relaxing of vascular smooth muscle mediated by the endothelial COX-2 reaction product prostacyclin.

Vasoconstriction via COX-2 Inhibition

A vascular consequence of inhibiting COX-2-mediated prostacyclin synthesis, which can promote myocardial infarction (MI) and stroke.

Maintenance of Renal Function via COX Isoforms

Physiological renal perfusion and renal vasodilation maintained jointly by COX-1 and COX-2 through the synthesis of $\text{PGE}_2$ and $\text{PGI}_2$.

Renal Vasodilation via Prostaglandins

The dilation of intrarenal blood vessels mediated by $\text{PGE}_2$ and $\text{PGI}_2$ to preserve glomerular filtration rate and perfusion.

Renal Impairment from COX Inhibition

Decreased renal blood flow and impaired glomerular filtration resulting from the inhibition of renal COX-1 and COX-2.

Inflammation and Pain in Injured Tissue via COX-2

Local tissue responses driven by COX-2-generated prostaglandin E2 ($\text{PGE}_2$) following mechanical or biochemical cellular trauma.

Analgesia via Peripheral COX-2 Inhibition

Pain relief achieved through the suppression of prostaglandin E2 ($\text{PGE}_2$) synthesis in damaged or inflamed peripheral tissues.

Fever and Pain in the Brain via COX-2

Central nervous system responses mediated by COX-2 activity, inducing febrile state and pain perception.

Antipyresis via Central COX-2 Inhibition

The therapeutic reduction of elevated body temperature achieved by blocking central COX-2-mediated prostaglandin synthesis.

Colorectal Cancer Promotion via COX-2

The biological progression and proliferation of colorectal neoplasia stimulated by chronic activity of the COX-2 enzyme.

Colorectal Cancer Protection via COX-2 Inhibition

The reduced incidence or delayed growth of colorectal tumors achieved by pharmacologically inhibiting the COX-2 enzyme.

NSAIDs (Nonsteroidal Anti-Inflammatory Drugs)

A class of cyclooxygenase inhibitors possessing anti-inflammatory, analgesic, and antipyretic properties, categorized into first-generation and second-generation agents.

First-

First-Generation NSAID Mechanism

Nonselective competitive inhibition of both cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes.

First-Generation NSAID Therapeutic Indications

Suppression of inflammation for disorders such as rheumatoid arthritis, osteoarthritis, and bursitis, alleviation of mild to moderate pain, reduction of fever, and relief of dysmenorrhea.

Reye's Syndrome

A severe, potentially fatal childhood condition characterized by encephalopathy and hepatic dysfunction, strongly linked to giving aspirin during viral illnesses.

Salicylism

A toxic clinical syndrome resulting from elevated aspirin levels, marked by tinnitus, sweating, headache, and dizziness.

Aspirin Adverse Effects in Pregnancy

Maternal anemia, risk of postpartum hemorrhage, and suppression of uterine contractions leading to prolonged labor.

Aspirin Dosage for Platelet Suppression

$325\,\text{mg}$ once daily for acute initial therapy, followed by $80\,\text{mg}$ once daily for chronic maintenance.

Aspirin Dosage for Fever and Mild Pain

$325-650\,\text{mg}$ administered orally every $4\,\text{hours}$ as needed in adults.

Aspirin Hypersensitivity

A severe pseudoallergic reaction occurring primarily in adults with asthma, rhinitis, and nasal polyps, triggering bronchospasm, urticaria, and angioedema.

Celecoxib Mechanism of Action

Selective inhibition of cyclooxygenase-2 (COX-2) while sparing COX-1, attenuating pain and inflammation with reduced gastric mucosal harm.

Celecoxib Cardiovascular Thrombotic Risk

Increased incidence of myocardial infarction and ischemic stroke resulting from suppression of vascular prostacyclin without concurrent inhibition of platelet thromboxane.

Celecoxib Contraindication in Cardiac Surgery

Absolute contraindication in the setting of coronary artery bypass graft (CABG) surgery due to elevated thrombotic event risk.

Celecoxib Sulfonamide Cross-Allergy

A hypersensitivity contraindication in patients with known sulfa allergies due to shared chemical sulfonamide structures.

Celecoxib and Warfarin Drug Interaction

Potentiation of anticoagulant effects and elevation of the international normalized ratio (INR), increasing major bleeding liability.

Celecoxib Contraindication in Third Trimester

Risk of premature closure of the fetal ductus arteriosus and fetal renal impairment induced by vascular prostaglandin inhibition.

Acetaminophen Mechanism of Action

Selective inhibition of prostaglandin synthesis within the central nervous system, with minimal inhibitory action in peripheral tissues.

Acetaminophen Anti-Inflammatory Limitation

Lack of peripheral anti-inflammatory and antirheumatic efficacy because inflammatory tissue peroxides neutralize its inhibitory action.

Acetaminophen Maximum Daily Dose for Healthy Adults

A ceiling of $4000\,\text{mg/day}$ to avoid saturated hepatic clearance pathways.

Acetaminophen Daily Limit for Chronic Alcohol Consumers

A reduced threshold of less than $2000\,\text{mg/day}$ due to elevated CYP2E1 activity and depleted endogenous glutathione stores.

Early Manifestations of Acute Acetaminophen Poisoning

Nausea, vomiting, diarrhea, diaphoresis, and abdominal discomfort occurring within the first $24\,\text{hours}$ of toxic ingestion.

Latency Period of Acetaminophen Hepatic Necrosis

A delay of $48-72\,\text{hours}$ following toxic ingestion before overt clinical jaundice, coagulopathy, and liver failure manifest.

Acetylcysteine Mechanism of Action

Direct replenishment of hepatic glutathione reserves to neutralize the toxic reactive metabolite NAPQI into nontoxic conjugates.

Optimal Timeframe for Acetylcysteine Administration

Within $8-10\,\text{hours}$ following acute acetaminophen overdose, conferring nearly $100\%$ protection against lethal hepatic necrosis.

Mineralocorticoids

Adrenal corticosteroids responsible for modulating electrolyte and fluid balance by promoting renal sodium reabsorption and potassium excretion.

Glucocorticoid Metabolic Influence

Promotion of hepatic gluconeogenesis, reduction of peripheral glucose utilization, and mobilization of amino acids leading to elevated blood glucose.

Glucocorticoid Non-Endocrine Indications

Management of inflammatory and autoimmune disorders such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, and asthma.

Cushingoid Physical Features from Glucocorticoid Excess

Fat redistribution resulting in a moon face, buffalo hump on the neck, truncal obesity, and slender extremities.

Glucocorticoid-Induced Bone Fragility

Accelerated osteoporosis and elevated fracture risk caused by suppressed osteoblast action, inhibited intestinal calcium absorption, and bone resorption.

Glucocorticoid-Induced Hyperglycemia

Elevation of blood glucose levels or precipitation of steroid-induced diabetes caused by hepatic glucose production and induced insulin resistance.

Glucocorticoid Peptic Ulcer Risk

Gastrointestinal mucosal damage and ulcer development resulting from inhibition of protective prostaglandins and enhanced gastric acid release.

Glucocorticoid-Induced Immunosuppression

Heightened susceptibility to bacterial, viral, and fungal infections resulting from leukocyte suppression and impaired cytokine synthesis.

Adrenal Axis Suppression from Glucocorticoid Therapy

Adrenocortical atrophy secondary to persistent negative feedback suppression of corticotropin-releasing hormone and adrenocorticotropic hormone.

Glucocorticoid Withdrawal Protocol

Stepwise tapering of the dosage over at least $7\,\text{days}$ or transitioning to morning dosing to allow endogenous adrenal recovery.

Alternate-Day Glucocorticoid Dosing Rationale

Administration of twice the daily dose every other morning to reduce hypothalamic-pituitary-adrenal axis suppression and decrease adverse effects.

Determinants of Glucocorticoid Differentiation

Variations in biologic half-life, relative mineralocorticoid potency, and relative glucocorticoid anti-inflammatory potency.

Etiology of Acute Gouty Arthritis

Deposition of monosodium urate microcrystals within synovium and joint tissues, instigating acute leukocyte activation and severe inflammation.

First-Line Pharmacotherapy for Acute Gout Attacks

High-dose nonsteroidal anti-inflammatory drugs (NSAIDs) such as naproxen, initiated immediately upon symptom onset.

Prednisone Role in Acute Gout

Rapid suppression of acute joint pain and inflammation in patients unable to tolerate or contraindicated for NSAID therapy.

Allopurinol Mechanism of Action

Inhibition of xanthine oxidase, the essential enzyme catalyzing the conversion of hypoxanthine and xanthine into uric acid.

Primary Therapeutic Goal of Urate-Lowering Therapy

Dissolution of existing urate tophi, prevention of new crystal nucleation, and reduction of acute flare frequency.

Role of Xanthine Oxidase Inhibitors in Acute Gouty Attacks

Ineffective for aborting active flares because they lack analgesic and anti-inflammatory properties, with potential to worsen attacks if started acutely.

Nursing Action for Allopurinol Hypersensitivity Rash

Immediate and permanent cessation of the medication, followed by urgent evaluation of hepatic and renal function.

First-Generation NSAID Renal Adverse Effects

Renal hypoperfusion, sodium retention, and acute renal failure resulting from suppression of vasodilatory renal prostaglandins ($\text{PGE}<em>2$ and $\text{PGI}</em>2$).

Comparison of GI Toxicity: Celecoxib vs Nonselective NSAIDs

Moderately decreased incidence of gastric ulceration and gastrointestinal bleeding due to selective sparing of COX-1 in the stomach lining.

Celecoxib and ACE Inhibitor Drug Interaction

Attenuated antihypertensive response and increased probability of precipitating acute renal failure through compounding hemodynamic renal compromise.

Glucocorticoid Cutaneous Adverse Effects

Atrophy of cutaneous connective tissue, petechiae, easy ecchymosis, impaired wound healing, and prominent purple striae.

Arachidonic Acid

The precursor fatty acid cleaved from membrane phospholipids that is converted by cyclooxygenase into prostaglandins, prostacyclin, and thromboxane.

Primary Enzymatic Target Sparing of Celecoxib

Cyclooxygenase-1 ($\text{COX}-1$), preserving baseline gastric mucosal prostaglandins and platelet thromboxane production at recommended therapeutic dosages.

Irreversible COX-1 Inactivation by Aspirin

Covalent acetylation of platelet cyclooxygenase-1, disabling thromboxane $A<em>2$ ($\text{TXA}</em>2$) synthesis for the entire $7-10\,\text{day}$ lifespan of the platelet.

Platelet Inhibition Difference Between Aspirin and Non-Aspirin NSAIDs

Aspirin produces irreversible platelet inhibition persisting for days, whereas traditional NSAIDs create reversible competitive inhibition that clears as circulating drug concentrations fall.

Ibuprofen and Aspirin Antiplatelet Drug Interaction

Competitive receptor antagonism where ibuprofen binds reversibly to the COX-1 active site, blocking aspirin from irreversibly acetylating platelets and compromising cardioprotection.

Cardiovascular Thrombotic Profile: Aspirin vs Non-Aspirin NSAIDs

Aspirin uniquely prevents myocardial infarction and ischemic stroke, whereas all non-aspirin first-generation and second-generation NSAIDs elevate thrombotic cardiovascular event risk.

Adult Aspirin Dosing Ceiling for Acute Rheumatic Fever

$5-8\,\text{g/day}$ administered orally in divided doses.

Adult Aspirin Dosage for Rheumatoid Arthritis

$3.6-5.4\,\text{g/day}$ administered orally in divided doses.

Pediatric Warning Against Aspirin Administration

Contraindicated in children and adolescents under $18\,\text{years}$ of age presenting with febrile viral illnesses due to the precipitating risk of Reye's syndrome.

High-Risk Patient Factors for NSAID Gastric Complications

Age $60\,\text{years}$ or older, ulcer or gastrointestinal bleeding history, concurrent anticoagulant or corticosteroid therapy, and daily consumption of $3$ or more alcoholic beverages.

Administration Method to Minimize Oral NSAID Gastric Distress

Ingestion of the dose with meals, food, or a full glass of water or milk to buffer direct mucosal irritation.

Celecoxib Interaction with Furosemide

Blunted loop diuretic and antihypertensive efficacy resulting from NSAID-induced suppression of intrarenal prostaglandin synthesis and ensuing fluid retention.

Celecoxib Interaction with Lithium

Decreased renal lithium excretion leading to elevated serum lithium concentrations and dangerous lithium toxicity.

Celecoxib Interaction with Fluconazole

Marked elevation of circulating celecoxib levels driven by fluconazole-mediated inhibition of the hepatic CYP2C9 metabolic pathway.

Mechanism Underlying NSAID Contraindication in Uncontrolled Hypertension

Inhibition of vasodilatory renal prostaglandins promoting renal sodium reabsorption, water retention, and systemic vasoconstriction.

Physiological Role of Prostaglandins on the Fetal Ductus Arteriosus

Sustaining functional vascular patency in utero; maternal NSAID exposure during late pregnancy induces premature ductal constriction and fetal pulmonary hypertension.

Formulations and Routes Available for Acetaminophen

Oral ($\text{PO}$), rectal suppository ($\text{PR}$), and intravenous solution ($\text{IV}$).

Inactivation Mechanism Behind Acetaminophen's Lack of Peripheral Anti-Inflammatory Action

High concentrations of cellular peroxides generated within inflamed peripheral tissues that neutralize the drug's inhibitory catalytic effect.

Toxic Reactive Intermediate in Acetaminophen Poisoning

N-acetyl-p-benzoquinone imine ($\text{NAPQI}$), an electrophilic metabolite that accumulates following glutathione depletion and causes hepatic necrosis.

Role of Cytochrome P450 2E1 (CYP2E1) in Acetaminophen Hepatotoxicity

An inducible hepatic isoenzyme upregulated by chronic ethanol consumption that accelerates the conversion of acetaminophen into the hepatotoxic intermediate NAPQI.

Characteristic Odor of Acetylcysteine (Mucomyst)

A noxious sulfurous scent resembling rotten eggs.

Clinical Manifestations of Delayed Acetaminophen Liver Necrosis ($48-72\,\text{hours}$)

Profoundly elevated serum transaminases (AST, ALT), progressive hyperbilirubinemia with jaundice, prolonged prothrombin time, and potential hepatic encephalopathy.

Pharmacological Classification of Prednisone

A synthetic intermediate-acting oral glucocorticoid providing robust anti-inflammatory and immunosuppressive activity with minimal mineralocorticoid potency.

Pharmacological Profile of Cortisone

A short-acting corticosteroid exhibiting equivalent glucocorticoid and mineralocorticoid actions, requiring hepatic conversion to hydrocortisone.

Anatomical Origin of Mineralocorticoids

The zona glomerulosa of the adrenal cortex, responsible for releasing aldosterone to govern electrolyte and water homeostasis.

Anatomical Origin of Endogenous Glucocorticoids

The zona fasciculata of the adrenal cortex, synthesizing cortisol under the direct regulatory control of pituitary adrenocorticotropic hormone (ACTH).

Glucocorticoid Catabolic Influence on Skeletal Muscle and Connective Tissue

Systemic proteolysis yielding amino acids for hepatic gluconeogenesis, producing proximal muscle weakness, atrophy, and dermal thinning.

Glucocorticoid-Driven Adipose Tissue Redistribution

Stimulated peripheral lipolysis paired with central lipogenesis, concentrating fat deposits onto the upper back, supraclavicular pads, abdomen, and cheeks.

Glucocorticoid Mechanism of Bone Demineralization

Direct suppression of osteoblast bone matrix synthesis, increased osteoclast-mediated resorption, and inhibited intestinal absorption of dietary calcium.